Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell...

Area of Science:

• Genetics
• Oncology
• Developmental Biology

Background:

• Germline genetic alterations can predispose individuals to both developmental disorders and cancers.
• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with complex genetic underpinnings.
• Understanding the genetic basis of rare syndromes is crucial for diagnosis and potential therapeutic strategies.

Observation:

• A case study of a boy presenting with neurodevelopmental delay and DLBCL.
• Identification of a de novo germline deletion on chromosome 2p16.3 encompassing the MSH6 and FBXO11 genes.
• MSH6's role in cancer development was ruled out based on tumor pathology.

Findings:

• The constitutional deletion of FBXO11 is identified as the cause of the patient's neurodevelopmental delay.
• FBXO11 protein regulates BCL-6 ubiquitination, a process essential for B cell differentiation.
• Somatic loss-of-function alterations in FBXO11 lead to BCL-6 overexpression, a known driver in DLBCL.

Implications:

• This case suggests a potential causative link between germline FBXO11 deletion and DLBCL development.
• The findings highlight FBXO11 as a potential tumor suppressor gene in B-cell lymphomagenesis.
• Further research is warranted to elucidate the precise mechanisms by which FBXO11 deletion contributes to DLBCL.